Management of Acute Coronary Syndromes Beyond the First Year: A Canadian Clinical Practice Survey

[1]  Samin K. Sharma,et al.  Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.

[2]  Deepak L. Bhatt,et al.  Ticagrelor in Patients with Stable Coronary Disease and Diabetes. , 2019, The New England journal of medicine.

[3]  Deepak L. Bhatt,et al.  Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. , 2019, Lancet.

[4]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[5]  J. Douketis,et al.  2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. , 2017, The Canadian journal of cardiology.

[6]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[7]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[8]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.